Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses.
Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, Genger JW, Endler L, Florian DM, Mühlgrabner V, Graninger M, Aberle SW, Husa AM, Shaw LE, Lercher A, Gattinger P, Torralba-Gombau R, Trapin D, Penz T, Barreca D, Fae I, Wenda S, Traugott M, Walder G, Pickl WF, Thiel V, Allerberger F, Stockinger H, Puchhammer-Stöckl E, Weninger W, Fischer G, Hoepler W, Pawelka E, Zoufaly A, Valenta R, Bock C, Paster W, Geyeregger R, Farlik M, Halbritter F, Huppa JB, Aberle JH, Bergthaler A. Agerer B, et al. Among authors: geyeregger r. Sci Immunol. 2021 Mar 4;6(57):eabg6461. doi: 10.1126/sciimmunol.abg6461. Sci Immunol. 2021. PMID: 33664060 Free PMC article.
Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes.
Tischer S, Kaireit T, Figueiredo C, Hiller O, Maecker-Kolhoff B, Geyeregger R, Immenschuh S, Blasczyk R, Eiz-Vesper B. Tischer S, et al. Among authors: geyeregger r. Int Immunol. 2012 Sep;24(9):561-72. doi: 10.1093/intimm/dxs059. Epub 2012 Jun 27. Int Immunol. 2012. PMID: 22740564
Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure.
Tischer-Zimmermann S, Salzer E, Bitencourt T, Frank N, Hoffmann-Freimüller C, Stemberger J, Maecker-Kolhoff B, Blasczyk R, Witt V, Fritsch G, Paster W, Lion T, Eiz-Vesper B, Geyeregger R. Tischer-Zimmermann S, et al. Among authors: geyeregger r. Front Immunol. 2023 Apr 5;14:988947. doi: 10.3389/fimmu.2023.988947. eCollection 2023. Front Immunol. 2023. PMID: 37090716 Free PMC article.
Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application.
Geyeregger R, Freimüller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, Lion T, Rammensee HG, Fischer G, Eiz-Vesper B, Lawitschka A, Matthes S, Fritsch G. Geyeregger R, et al. PLoS One. 2013 Apr 22;8(4):e59592. doi: 10.1371/journal.pone.0059592. Print 2013. PLoS One. 2013. PMID: 23630567 Free PMC article.
First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation.
Geyeregger R, Freimüller C, Stemberger J, Artwohl M, Witt V, Lion T, Fischer G, Lawitschka A, Ritter J, Hummel M, Holter W, Fritsch G, Matthes-Martin S. Geyeregger R, et al. J Immunother. 2014 May;37(4):245-9. doi: 10.1097/CJI.0000000000000034. J Immunother. 2014. PMID: 24714358
47 results